Compare iShares Semiconductor ETF (SOXX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Semiconductor ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares Semiconductor ETF trades at $567.95 (market cap $48.19B), while Vertex Pharmaceuticals Incorporated trades at $514 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.6× iShares Semiconductor ETF's market cap, and iShares Semiconductor ETF is more actively traded (10,257,578 versus 1,487,944). Which is the better fit depends on your goals — on Pluang, investors hold iShares Semiconductor ETF for 46 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SOXX | VRTX | |
|---|---|---|
Market Cap | $48.19B | $127.55B |
Volume | 10,257,578 | 1,487,944 |
Sector | Sector/Thematic | Health |
52-Week High | $655.01 | $557.96 |
52-Week Low | $268.10 | $407.37 |
Typical Hold Time | 46 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOXX trades at $582.94, down 1.1% today but maintains a bullish technical stance with strong moving average support. The semiconductor ETF benefits from AI-driven demand, with recent news highlighting sector gains and positive earnings momentum. However, high valuations and Michael Burry's expanded short position signal caution amid the AI boom.
Outlook remains positive due to structural AI growth, but risks include valuation concerns and sector concentration. Earnings growth supports further upside, though macroeconomic conditions and competitive pressures could temper returns. Investors should balance optimism with prudent risk management.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Semiconductor ETF
SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
